A new analysis of the JUPITER trial, released today at the American Heart Association meeting in Orlando, Florida, demonstrates that CRESTOR (rosuvastatin calcium) 20mg reduced first major cardiovascular events by 46%.
Cardiovascular disease is the leading cause of death in Canadian women and is no longer considered a "man's disease." In fact, women are more likely than men to die of a heart attack or stroke. Women are also ten times more likely to die from cardiovascular disease than from any other disease and six times more likely to die from a heart attack or stroke than from breast cancer.(2)
"Until now, we've had limited information about the benefits of primary prevention in women," said Dr. Jacques Genest, Director, Cardiology Division, McGill University Health Centre. "The results of the JUPITER trial demonstrate that women can reduce their risk of cardiovascular events with effective treatments such as rosuvastatin 20mg."
Nearly one half of all cardiovascular events occur in people who are apparently healthy and who have low or normal levels of low density lipoprotein cholesterol (LDL-C), a traditional indicator of cardiovascular risk.(3) hsCRP is a type of protein naturally produced in the body that is thought to be a marker of inflammation and increased risk of cardiovascular and other diseases.